Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr 15;200(8):2757-2766.
doi: 10.4049/jimmunol.1602090. Epub 2018 Mar 9.

15-epi-Lipoxin A4, Resolvin D2, and Resolvin D3 Induce NF-κB Regulators in Bacterial Pneumonia

Affiliations

15-epi-Lipoxin A4, Resolvin D2, and Resolvin D3 Induce NF-κB Regulators in Bacterial Pneumonia

Ho Pan Sham et al. J Immunol. .

Abstract

Specialized proresolving mediators (SPMs) decrease NF-κB activity to prevent excessive tissue damage and promote the resolution of acute inflammation. Mechanisms for NF-κB regulation by SPMs remain to be determined. In this study, after LPS challenge, the SPMs 15-epi-lipoxin A4 (15-epi-LXA4), resolvin D1, resolvin D2, resolvin D3, and 17-epi-resolvin D1 were produced in vivo in murine lungs. In LPS-activated human bronchial epithelial cells, select SPMs increased expression of the NF-κB regulators A20 and single Ig IL-1R-related molecule (SIGIRR). Of interest, 15-epi-LXA4 induced A20 and SIGIRR in an lipoxin A4 receptor/formyl peptide receptor 2 (ALX/FPR2) receptor-dependent manner in epithelial cells and in murine pneumonia. This SPM regulated NF-κB-induced cytokines to decrease pathogen-mediated inflammation. In addition to dampening lung inflammation, surprisingly, 15-epi-LXA4 also enhanced pathogen clearance with increased antimicrobial peptide expression. Taken together, to our knowledge these results are the first to identify endogenous agonists for A20 and SIGIRR expression to regulate NF-κB activity and to establish mechanisms for NF-κB regulation by SPMs for pneumonia resolution.

PubMed Disclaimer

Conflict of interest statement

Disclosures

C.N.S. is an inventor on patents (resolvins) assigned to BWH and licensed for clinical development. The interests of C.N.S. were reviewed and are managed by the Brigham and Women’s Hospital and Partners HealthCare in accordance with their conflict of interest policies. B.D.L. is an inventor on patents (resolvins) assigned to BWH and licensed to Resolvyx Pharmaceuticals. The interests of B.D.L. were reviewed and are managed by the Brigham and Women’s Hospital and Partners HealthCare in accordance with their conflict of interest policies. The remaining authors declare no conflict of interest.

Figures

Figure 1
Figure 1. SPMs are endogenously produced during LPS-induced lung inflammation and decrease airway epithelial inflammatory response
(A) Representative multiple reaction-monitoring (MRM) chromatogram for 15-epi-LXA4, RvD1, 17-epi-RvD1, RvD2 and RvD3 and (B) MS/MS spectrum obtained from infected murine lung used for the identification and quantification of SPMs. (C) Calu-3 cells were exposed (24 hrs, 37°C) to LPS or vehicle (media only) in the presence of 15-epi-LXA4 or vehicle (media only) and levels of CXCL8 in the supernatant were measured by ELISA. NF-κB activation in Calu-3 cells was detected by NF-κB phospho-p65 at 3 hrs (D) and 24 hrs (E) after LPS with 15-epi-LXA4 or vehicle. In all experiments, 15-epi-LXA4 (100nM) was added 30 minutes before LPS (10 μg/mL). Values represent the mean ± SEM n = 4-8 per group. * P <0.05, ** P <0.01
Figure 2
Figure 2. 15-epi-LXA4 increases epithelial expression of select negative regulators of NF-κB
(A) A20, (B) ST2 and (C, D) SIGIRR expression in Calu-3 cells exposed to LPS (10 μg/mL) for 3 hrs was measured by qPCR (A-C) and Western blot (D). The time course for LPS-induced changes in relative RNA levels of (E) A20, (F) ST2 and (G) SIGIRR was measured by qPCR in Calu-3 cells incubated (30 min, 37°C) with 15-epi-LXA4 (100 nM) or vehicle (media) prior to the addition of LPS (10 μg/mL); * P <0.05 vs baseline, # P <0.05 vs vehicle by two-way ANOVA. In some experiments, cells were exposed to an ALX/FPR2 antagonist WRW4 (210nM) and (H) A20 and (I) SIGIRR RNA levels determined by qPCR. (J) A20 and (K) SIGIRR RNA were determined in 15-epi-LXA4- or vehicle-exposed Calu-3 cells infected with E. coli (106 CFU) for 24 hrs. Results are expressed as mean ± SEM n = 3-12 per group. * P <0.05, ** P <0.01
Figure 3
Figure 3. SPMs selectively regulate A20 and SIGIRR
Structure-activity relationships for A20 and SIGIRR induction in airway epithelial cells were determined for (A) 15-epi-LXA4 and select D- series resolvins that inhibit NF-κB. (B, C) Calu-3 cells were exposed to 15-epi-LXA4, 17-epi-RvD1, RvD2, RvD3 (100nM each) or vehicle (media) prior to LPS (10 μg/mL, 3hrs). RNA levels of (B) A20 and (C) SIGIRR were measured by qPCR. (D) Calu-3 cells were treated with 15-epi-LXA4 (10nM), a combination of 15-epi-LXA4, 17-epi-RvD1 and RvD3 (10nM each), or vehicle (PBS) followed by exposure to IL-1β (1ng/mL, 3 hrs, 37°C), protein isolation and Western blot for phosphorylated NF-κB p65. Results are expressed as mean ± SEM, n = 4-8 per group. * P <0.05, ** P <0.01
Figure 4
Figure 4. 15-epi-LXA4 enhances E. coli clearance and decreases lung inflammation
The murine left lung was inoculated with E. coli (106 CFU); select animals were exposed to 15-epi-LXA4 (100ng, IV), ciprofloxacin (0.2mg/kg, approximately IC50, IP) or vehicle (0.9% saline, IV) 1 hr after E. coli infection. (A) CFU were determined in lung homogenates 6 hrs after E.coli infection. (B) Phosphorylation of NF-κB p65 was assessed in lung homogenates 6 hrs after E. coli infection. (C) A20 and (D) SIGIRR RNA in lung were determined 24 hrs after E. coli infection. (E) In BAL fluid obtained 24 hrs after infection, neutrophils were identified by flow cytometry (CD45+ CD11b+ CD11c Ly6G+). (F) In BAL fluid obtained 24 hrs after infection, levels of CXCL1 were determined by ELISA. Results are expressed as mean ± SEM, n = 3-12 per group. * P <0.05
Figure 5
Figure 5. 15-epi-LXA4 restrains bacterial growth by increasing airway epithelial expression of antimicrobial peptides
Calu-3 cells were exposed to E. coli (MOI 10:1) for 3 hrs following 15-epi-LXA4 (100nM) or vehicle and (A) the bacterial growth index was determined. Calu-3 cell expression of the anti-microbial peptides (B) bacterial permeability inducing protein (BPI) and (C) LL-37 was measured by qPCR. (D) Calu-3 cell expression of LL-37 protein in the setting of 15-epi-LXA4 (100nM) or vehicle was assessed by Western blot 3 hrs after LPS stimulation. The impact of 15-epi-LXA4 (100 ng, IV) or vehicle (0.9% saline, IV) given 1 hr after E. coli on expression of (E) mBPI and (F) mCRAMP was measured in mouse lung RNA obtained 24 hrs post-infection. (G) Mouse left lungs were inoculated with E. coli (107 CFU) and CFU were determined 24 hrs after inoculation of wild type (WT) or Cnlp−/− mice given 15-epi-LXA4 (100 ng, IV) or vehicle (0.9% saline, IV) 1 hr after E. coli. Results are expressed as mean ± SEM, n = 4-8 per group. * P <0.05
Figure 6
Figure 6. ALX/FPR2−/− mice have delayed resolution of pathogen-induced lung inflammation
(A) WT and ALX/FPR2−/− mice were infected with E.coli (106 CFU) and the time course for lung neutrophil trafficking was enumerated by flow cytometry at baseline, 6 hrs, 24 hrs, 48 hrs and 72 hrs post infection; *P <0.05 by two-way ANOVA. (B) BALF neutrophils (CD45+CD11B+CD11cLy6G+) from WT and ALX/FPR2−/− mice given 15-epi-LXA4 (100ng, IV) or vehicle (0.9% saline, IV) 1 hr after infection. (C) BALF levels of CXCL1 from WT and ALX/FPR2−/− mice 24 hrs post-infection were measured by ELISA. (D) mCRAMP and (E) mBPI expression were measured in lung tissues by qPCR 24 hrs after infection. (F) Phosphorylation of NF-κB p65 in infected lung tissue was monitored by Western blot. Results are expressed as mean ± SEM, n = 3-12 per group. * P <0.05

Similar articles

Cited by

References

    1. Dalli J, Colas RA, Quintana C, Barragan-Bradford D, Hurwitz S, Levy BD, Choi AM, Serhan CN, Baron RM. Human Sepsis Eicosanoid and Proresolving Lipid Mediator Temporal Profiles: Correlations With Survival and Clinical Outcomes. Crit Care Med. 2017;45:58–68. - PMC - PubMed
    1. Nathan C. Fresh approaches to anti-infective therapies. Sci Transl Med. 2012;4:140sr142. - PMC - PubMed
    1. Mizgerd JP. Lung infection–a public health priority. PLoS Med. 2006;3:e76. - PMC - PubMed
    1. Gilroy D, De Maeyer R. New insights into the resolution of inflammation. Semin Immunol. 2015;27:161–168. - PubMed
    1. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510:92–101. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources